CoChat

Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase

Open access
Bilen, Ozlem, Ballantyne, Christie M. · 2016 · Current Atherosclerosis Reports

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

Bempedoic acid (ETC-1002), a novel therapeutic approach for low-density lipoprotein cholesterol (LDL-C) lowering, inhibits ATP citrate lyase (ACL), an enzyme involved in fatty acid and cholesterol synthesis. Although rodent studies suggested potential effects of ACL inhibition on both fatty acid and cholesterol synthesis, studies in humans show an effect only on cholesterol synthesis. In phase 2 studies, ETC-1002 reduced LDL-C as monotherapy, combined with ezetimibe, and added to statin therapy, with LDL-C lowering most pronounced when ETC-1002 was combined with ezetimibe in patients who cannot tolerate statins. Whether clinically relevant favorable effects on other cardiometabolic risk factors such as hyperglycemia and insulin resistance occur in humans is unknown and requires further investigation. Promising phase 2 results have led to the design of a large phase 3 program to gain more information on efficacy and safety of ETC-1002 in combination with statins and when added to ezetimibe in statin-intolerant patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11883-016-0611-4

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Major metabolic pathways affected by bempedoic acid (ETC-1002) in humans as supported by clinical trial data. Animal data suggested additional effects on triglyceride metabolism via ACL inhibition and other cardiometabolic pathways via AMP-activated protein kinase (AMPK) activation. ACL ATP citrate lyase, Acetyl-CoA acetyl coenzyme A, HMG-S HMG-CoA synthase, HMG-R HMG-CoA reductase
Fig. 1 Major metabolic pathways affected by bempedoic acid (ETC-1002) in humans as supported by clinical trial data. Animal data suggested additional effects on triglyceride metabolism via ACL inhibition and other cardiometabolic pathways via AMP-activated protein kinase (AMPK) activation. ACL ATP citrate lyase, Acetyl-CoA acetyl coenzyme A, HMG-S HMG-CoA synthase, HMG-R HMG-CoA reductaseCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 121

Metadata

Authors
Bilen, O., & Ballantyne, C. M.
Affiliations
Houston Methodist (US)
Corresponding author
Ballantyne, Christie M.
Venue
Current Atherosclerosis Reports
Published
2016-09-23
Volume
18
Issue
10
Pages
61-61
ISSN
  • 1523-3804 (ISSN-L)
  • 1534-6242
OpenAlex
W2521647868
Cited by
119
References
28
Citations by year
2026: 7 · 2025: 15 · 2024: 17 · 2023: 12 · 2022: 13 · 2021: 18 · 2020: 10 · 2019: 14 · 2018: 8 · 2017: 5
FWCI
1.85
Type
journal article
Language
en
Open access
Locations
  • Current Atherosclerosis Reports (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
bempedoic acid, ATP-citrate lyase inhibition, LDL cholesterol lowering, statin intolerance, cholesterol biosynthesis, fatty acid synthesis, hypertriglyceridemia, insulin resistance, cardiometabolic risk factors
MeSH terms
Ezetimibe, Anticholesteremic Agents, ATP Citrate (pro-S)-Lyase, Dicarboxylic Acids, Drug Therapy, Combination, Fatty Acids, Humans, Hypercholesterolemia, Cholesterol, LDL, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase. https://app.cochat.ai/papers/10.1007/s11883-016-0611-4
The paper
Bilen, O., & Ballantyne, C. M. (2016). Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase. Current Atherosclerosis Reports. https://doi.org/10.1007/s11883-016-0611-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.